Non-gene-edited, CD19-targeted, allogeneic CAR-T cell therapy for relapsed or refractory B-cell acute lymphoblastic leukemia: an open-label, single-arm phase 1 study.
- DOI
- 10.1038/s41409-026-02929-7
- Published
- 2026 Aug
- Container
- Bone marrow transplantation
- Publisher
- Not recorded
- Open access
- unknown
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1038/s41409-026-02929-7,
title = {Non-gene-edited, CD19-targeted, allogeneic CAR-T cell therapy for relapsed or refractory B-cell acute lymphoblastic leukemia: an open-label, single-arm phase 1 study.},
author = {Wu C and Xue L and Wu M and Li S and Xu Q and Liu K and Li H and Xu H and Yang L and Wang T and Jin R and Wang X},
year = {2026},
journal = {Bone marrow transplantation},
doi = {10.1038/s41409-026-02929-7},
url = {https://doi.org/10.1038/s41409-026-02929-7}
}RIS
TY - JOUR TI - Non-gene-edited, CD19-targeted, allogeneic CAR-T cell therapy for relapsed or refractory B-cell acute lymphoblastic leukemia: an open-label, single-arm phase 1 study. AU - Wu C AU - Xue L AU - Wu M AU - Li S AU - Xu Q AU - Liu K AU - Li H AU - Xu H AU - Yang L AU - Wang T AU - Jin R AU - Wang X PY - 2026 JO - Bone marrow transplantation DO - 10.1038/s41409-026-02929-7 UR - https://doi.org/10.1038/s41409-026-02929-7 ER -
APA
C, W., L, X., M, W., S, L., Q, X., K, L., H, L., H, X., L, Y., T, W., R, J., & X, W. (2026). Non-gene-edited, CD19-targeted, allogeneic CAR-T cell therapy for relapsed or refractory B-cell acute lymphoblastic leukemia: an open-label, single-arm phase 1 study.. Bone marrow transplantation. https://doi.org/10.1038/s41409-026-02929-7
Source records
- pubmed · retrieved 2026-11-10T14:20:44.048Z